KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $171.3 million.

  • Supernus Pharmaceuticals' Receivables - Net rose 1777.48% to $171.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.3 million, marking a year-over-year increase of 1777.48%. This contributed to the annual value of $142.1 million for FY2024, which is 144.15% down from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Receivables - Net is $171.3 million, which was up 1777.48% from $140.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Receivables - Net's 5-year high stood at $171.3 million during Q3 2025, with a 5-year trough of $127.1 million in Q1 2021.
  • Its 5-year average for Receivables - Net is $146.9 million, with a median of $145.1 million in 2022.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Receivables - Net skyrocketed by 2274.9% in 2022 and then tumbled by 1360.66% in 2023.
  • Supernus Pharmaceuticals' Receivables - Net (Quarter) stood at $148.9 million in 2021, then rose by 11.12% to $165.5 million in 2022, then dropped by 12.9% to $144.2 million in 2023, then dropped by 1.44% to $142.1 million in 2024, then rose by 20.54% to $171.3 million in 2025.
  • Its Receivables - Net was $171.3 million in Q3 2025, compared to $140.8 million in Q2 2025 and $145.6 million in Q1 2025.